Kodiak Sciences Inc.
Zenkuda
diabetic retinopathy
Date
TBD
FDA decision · Date TBD estimated
What's at stake
The FDA's approval decision on Zenkuda for diabetic retinopathy is due Date TBD. A green light opens the market; a complete response letter (CRL) usually sinks the stock.
Primary source
· SEC 8-K
verified 14h ago
“Combined with the previously reported Phase 3 study readouts (GLOW1, BEACON and DAYLIGHT), Zenkuda now has a multi-indication BLA-ready profile.”